Results 191 to 200 of about 19,628 (262)

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

BMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao, Rui Qu, Zan Dai, Xiqun Jiang, Xu Zhen   +4 more
wiley   +1 more source

Mimic, target, and adapt: Cell membrane‐coated nanoplatforms for precision and immune‐guided cancer treatment

BMEMat, EarlyView.
This Perspective explores the emerging landscape of cell membrane‐coated nanoparticles (CM‐NPs) as intelligent, immune‐compatible platforms for cancer therapy. Highlighting design strategies, translational challenges, and competitive positioning, it outlines how integrating biomimetic targeting with advanced analytical and manufacturing tools could ...
A. K. M. M. Alam, Xiaojun Cai, Malik Ihsan Ullah Khan, Robert Musiol, Quazi T. H. Shubhra   +4 more
wiley   +1 more source

Integrated spherical nucleic acid nanoreactor mobilizes targeted PD‐L1 proteolysis and cuproptosis for robust breast cancer immunotherapy

BMEMat, EarlyView.
This study provides an integrated spherical nucleic acid nanoreactor (denoted as AMCuD) for targeted PD‐L1 degradation and chemo‐dynamically enhanced cuproptosis to synergically elicit robust immunotherapy against the triple‐negative breast cancer (TNBC) growth, recurrence and metastasis.
Ningxi Li, Honglin Huang, Qianyi Zeng, Li Zeng, Ziman Yang, Jinyang Shen, Shun Li, Hong Yang, Yiyao Liu, Chunhui Wu   +9 more
wiley   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Machine learning‐assisted clone selection for intensified cell culture processes

Biotechnology Progress, EarlyView.
Abstract Intensified fed‐batch processes are becoming increasingly prevalent among biomanufacturers due to their superior space–time yields relative to traditional, non‐intensified fed‐batch processes. However, the shift towards intensified manufacturing has unexpectedly made optimal clone selection more challenging.
Nicolas Wolnick, John Schmitt, Christian Siltanen, Julia Armstrong, Shannon Hendrick, Ariel Atchley, Brandon Downey   +6 more
wiley   +1 more source

Characterization and immunogenicity of nanoparticle vaccines displaying embecovirus spike proteins

Biotechnology Progress, EarlyView.
Virus‐like particle vaccines displaying spike proteins from OC43, HKU1 A, and HKU1 B were evaluated in mice for their ability to elicit antibodies against the spike proteins from OC43, HKU1 A, HKU1 B, and HKU1 C. Abstract Endemic human coronaviruses OC43 and HKU1 cause widespread respiratory infections and can be associated with severe illness in ...
Peter J. Halfmann, Augustine Duffy, Alex Wee, Noah Anderson, Jackson Terrell, Yoshihiro Kawaoka, Ravi S. Kane   +6 more
wiley   +1 more source

Chemotherapeutic Potential of Fluorouracil‐Platinum (IV) Prodrugs Against Cisplatin‐Resistant Colorectal Cancer Cells

Chemistry – A European Journal, EarlyView.
ABSTRACT Fluorouracil‐platinum(IV) prodrugs represent a novel class of multimechanistic chemotherapeutics with enhanced anticancer potential. The prodrugs PtIVP‐5FUMeOBut and PtIV56‐5FUMeOBut were actualized by derivatising the clinical drug 5‐fluorouracil (5FU) and coordinating it to platinum(IV) complexes, leveraging the established cytotoxicity of ...
Maria George Elias, Aleen Khoury, Shadma Fatima, Timothy J. Mann, Shawan Karan, Meena Mikhael, Paul de Souza, Christopher P. Gordon, Kieran F. Scott, Janice R. Aldrich‐Wright   +9 more
wiley   +1 more source

A CASE OF ACCESSORY BREAST CANCER

Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2004
Hirotoshi TAKEMOTO, Yoshiaki NAKANO, Hirosi YANO, Shigeru OKAMOTO, Sadayuki HORIKI, Takushi MONDEN   +5 more
openaire   +2 more sources

Carbon Dots for Cancer Theranostics: Synthesis Strategies, Luminescence Properties, and Advances in Bioimaging‐Guided Diagnosis and Therapy

Chemistry – A European Journal, EarlyView.
Lighting up the path to precision oncology: This review comprehensively summarizes the rational design of carbon dots (CDs), elucidating how core size, surface chemistry, and heteroatom doping dictate their luminescence mechanisms. Special emphasis is placed on engineering NIR‐II emissive CDs for deep‐tissue imaging.
Zekun Yan, Yupeng Liu, Jinyun Tan, Songnan Qu   +3 more
wiley   +1 more source

Accessory breasts in the labia majora

Journal of British Surgery, 1927
Robert Purves, J A Hadley
openaire   +1 more source